胰腺癌的立体定向体部放疗：肿瘤内科医生的批判性综述
Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist.
作者信息
Kim Samuel K, Wu Cheng-Chia, Horowitz David P
机构信息
Department of Radiation Oncology, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY 10032, USA.
出版信息
J Gastrointest Oncol. 2016 Jun;7(3):479-86. doi: 10.21037/jgo.2015.10.01.
Abstract
With recent advances in imaging modalities and radiation therapy, stereotactic body radiotherapy (SBRT) has allowed for the delivery of high doses of radiation with accuracy and precision. As such, SBRT has generated favorable results in the treatment of several cancers. Although the role of radiation has been controversial for the treatment of pancreatic ductal adenocarcinoma (PDAC) due to rather lackluster results in clinical trials, SBRT may offer improved outcomes, enhance the quality of life, and aid in palliative care settings for PDAC patients. This review delineates the role of SBRT in the treatment of PDAC, presents the defining principles of radiation biology and the radiation oncology work flow, and discusses the prospects of new treatment regimens involving tumor immunology and radiation therapy.
摘要
随着成像技术和放射治疗的最新进展，立体定向体部放射治疗（SBRT）已能够精确地给予高剂量辐射。因此，SBRT在多种癌症的治疗中取得了良好效果。尽管由于临床试验结果相当平淡，放射治疗在胰腺导管腺癌（PDAC）治疗中的作用一直存在争议，但SBRT可能会改善PDAC患者的治疗效果、提高生活质量并有助于姑息治疗。本文综述阐述了SBRT在PDAC治疗中的作用，介绍了放射生物学的定义原则和放射肿瘤学工作流程，并讨论了涉及肿瘤免疫学和放射治疗的新治疗方案的前景。
相似文献
1
Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist.
J Gastrointest Oncol. 2016 Jun;7(3):479-86. doi: 10.21037/jgo.2015.10.01.
2
Prognostic Factors for Elderly Patients Treated With Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma.
Front Oncol. 2018 Jul 27;8:282. doi: 10.3389/fonc.2018.00282. eCollection 2018.
3
Stereotactic Body Radiotherapy - Current Indications.
Klin Onkol. 2019 Winter;32(1):10-24. doi: 10.14735/amko201910.
4
Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
Cancer. 2017 Sep 15;123(18):3486-3493. doi: 10.1002/cncr.30706. Epub 2017 May 10.
5
Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy.
Strahlenther Onkol. 2016 Dec;192(12):875-885. doi: 10.1007/s00066-016-1053-1. Epub 2016 Oct 24.
6
Stereotactic body radiation therapy for palliative management of pancreatic adenocarcinoma in elderly and medically inoperable patients.
Oncotarget. 2018 Mar 27;9(23):16427-16436. doi: 10.18632/oncotarget.24713.
7
The Evolving Field of Stereotactic Body Radiation Therapy in Pancreatic Cancer.
Pancreas (Fairfax). 2019;3(1):9-14. doi: 10.17140/POJ-3-110. Epub 2019 Nov 6.
8
Advances of stereotactic body radiotherapy in pancreatic cancer.
Chin J Cancer Res. 2015 Aug;27(4):349-57. doi: 10.3978/j.issn.1000-9604.2015.04.12.
9
Reirradiation spine stereotactic body radiation therapy for spinal metastases: systematic review.
J Neurosurg Spine. 2017 Oct;27(4):428-435. doi: 10.3171/2017.2.SPINE16976. Epub 2017 Jul 14.
10
Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET.
Pract Radiat Oncol. 2017 Mar-Apr;7(2):120-125. doi: 10.1016/j.prro.2016.09.002. Epub 2016 Sep 7.
引用本文的文献
1
Stereotactic body radiotherapy for unresectable or locally recurrent pancreatic cancer: A single centre experience.
J Radiosurg SBRT. 2025;9(3):207-213.
2
Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial.
BMC Cancer. 2022 Aug 8;22(1):865. doi: 10.1186/s12885-022-09974-7.
3
Stereotactic ablative radiotherapy for oligometastatic breast cancer in elderly patients.
Transl Cancer Res. 2020 Jan;9(Suppl 1):S197-S206. doi: 10.21037/tcr.2019.08.29.
4
HIF2 Regulates Intestinal Wnt5a Expression.
Front Oncol. 2021 Nov 25;11:769385. doi: 10.3389/fonc.2021.769385. eCollection 2021.
5
Dosimetric and radiobiological comparison of treatment plan between CyberKnife and EDGE in stereotactic body radiotherapy for pancreatic cancer.
Sci Rep. 2021 Feb 18;11(1):4065. doi: 10.1038/s41598-021-83648-5.
6
Radiomics-Based Outcome Prediction for Pancreatic Cancer Following Stereotactic Body Radiotherapy.
Cancers (Basel). 2020 Apr 24;12(4):1051. doi: 10.3390/cancers12041051.
7
Impact of abdominal compression on setup error and image matching during radical abdominal radiotherapy.
Tech Innov Patient Support Radiat Oncol. 2019 Dec 16;12:28-33. doi: 10.1016/j.tipsro.2019.11.003. eCollection 2019 Dec.
8
Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer.
Cancer Res. 2019 May 1;79(9):2327-2338. doi: 10.1158/0008-5472.CAN-18-1785.
9
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Front Immunol. 2018 Aug 15;9:1878. doi: 10.3389/fimmu.2018.01878. eCollection 2018.
10
Prognostic Factors for Elderly Patients Treated With Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma.
Front Oncol. 2018 Jul 27;8:282. doi: 10.3389/fonc.2018.00282. eCollection 2018.
本文引用的文献
1
Immune microenvironment as a factor of breast cancer progression.
Diagn Pathol. 2015 Jun 26;10:79. doi: 10.1186/s13000-015-0316-y.
2
Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.
Lancet Oncol. 2015 Jul;16(7):795-803. doi: 10.1016/S1470-2045(15)00054-6. Epub 2015 Jun 18.
3
Targeting roles of inflammatory microenvironment in lung cancer and metastasis.
Cancer Metastasis Rev. 2015 Jun;34(2):319-31. doi: 10.1007/s10555-015-9570-4.
4
[Possibilities of stereotactic radiotherapy in the palliative treatment of patients with pancreatic cancer].
Vopr Onkol. 2015;61(1):121-4.
5
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
N Engl J Med. 2015 May 21;372(21):2006-17. doi: 10.1056/NEJMoa1414428. Epub 2015 Apr 20.
6
Pembrolizumab for the treatment of non-small-cell lung cancer.
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.
7
A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer.
Cancer Med. 2015 Jul;4(7):1051-9. doi: 10.1002/cam4.447. Epub 2015 Mar 31.
8
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.
9
Stereotactic body radiotherapy (SBRT) in the management of extracranial oligometastatic (OM) disease.
Br J Radiol. 2015 Apr;88(1048):20140712. doi: 10.1259/bjr.20140712. Epub 2015 Feb 13.
10
Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer.
Eur J Gastroenterol Hepatol. 2015 Mar;27(3):259-64. doi: 10.1097/MEG.0000000000000283.
Zotero 插件